Not Applicable
The present invention generally relates to sensors.
The integration of silicon-fabricated microneedles with conventional silicon complementary metal-oxide semiconductor (“CMOS”) circuitry is of utmost importance in perpetuating the miniaturization efforts of body-worn medical devices. Despite the current state of semiconductor miniaturization and packaging, the creation of a heterogeneous system comprised of microneedle-based sensors and the CMOS circuitry required to transduce the signals generated by such devices has posed a formidable challenge to those aiming to create low-profile, highly-integrated body-worn sensors for the quantification of physiological or biochemical signals. Indeed, leveraging state-of-the-art semiconductor processing and packaging methods in conjunction with CMOS-based circuitry and recent developments in minimally-invasive silicon-based microneedle devices for physiological and biochemical sensing would enable the construction of a self-contained sensing system in a single package.
U.S. Pat. No. 8,506,529 for a Method and structure of monolithetically integrated microneedle biochip discloses a method and device using CMOS and MEMS fabrication techniques for making an integrated microneedle device with integrated circuits. Merely by way of example, the technology can be applied to bio and chemical sensing, and other bioMEMS applications. In some embodiments, the integrated circuits are completed using standard IC processes. For example, an array of microneedles are fabricated on top of the IC substrate followed by formation of micro fluidic channels in the substrate. On-chip integrated circuits enable real-time sensing and intelligent drug delivery.
U.S. Pat. No. 5,953,306 for a Micro needle probe apparatus having probes cantilevered over respective electronic circuits, moving medium memory device including same and method of making same discloses micro needle probe apparatus that includes a probe and its associated electronic circuit. The electronic circuit is formed in a substrate and includes at least one metal interconnection layer. The probe is cantilevered over the electronic circuit and is composed of a metal probe arm, a support post that anchors one end of the probe arm to the substrate, and a micro needle mounted adjacent the moveable end of the probe arm. The probe apparatus may be used as the read/write mechanism of the moving-medium type memory device.
U.S. Pat. No. 8,452,369 for a CMOS compatible microneedle structures discloses an electronic device for sensing and/or actuating, the electronic device comprising at least one microneedle (10) on a substrate (1), each of the microneedles (10) comprising at least one channel (7, 8) surrounded by an insulating layer (6).
Prior art solutions have been concerned with the integration of silicon-based microneedle arrays and CMOS circuitry as discrete devices populating a printed circuit board; in certain circumstances, these metallic wires are coated with a layer of metal salt, such as a silver wire functionalized on the surface with a layer of silver chloride. Such integration fails to minimize device footprint, especially in x-y dimensions, since device area constitutes the summation of the area of any discrete CMOS circuitry, microneedle sensor(s), and area devoted to interconnect between these two entities on said printed circuit board. Under such a design philosophy, efforts have largely been devoted to ultra-large scale integration of CMOS circuitry and the creation of CMOS systems-on-a-chip to minimize the number of discrete CMOS devices populating a sensing system. Likewise, recent efforts have been directed at reducing the number of components required to realize microneedle-mediated sensing via the integration of electrophysiological and electrochemical sensors on self-contained solid microneedle devices, thereby obviating the need for separate hollow microneedle-based lumens for physiological fluid extraction and an adjoining chamber for which the chemical reaction and/or electrochemical detection are intended to occur. The heterogeneous integration of CMOS- and microneedle-based capabilities into a single package would facilitate a novel means to the construction of self-contained sensor-transducer devices that require substantially less footprint than conventional discrete constituents that comprise current body-worn sensing systems can provide.
The technology described herein relates to methods of integration and packaging of heterogenous semiconductor substrates.
One aspect of the present invention is a skin-adorned physiological or biochemical sensing system. The system comprises a first substrate and a second substrate. The first substrate features an anterior and a posterior surface. The first substrate comprises an array of solid microneedles on the anterior surface designed to penetrate a biological interface to access a physiological fluid or tissue. Each microneedle contains an addressable metal electrode located on the surface of the microneedle which is in electrical communication with a metal surface located on the posterior surface of the first substrate by means of a conductive conduit, to form a sensor component capable of electrical interface with the physiological fluid or tissue. The second substrate has an anterior and a posterior surface. The second substrate comprises integrated circuitry on the anterior surface designed to transduce at least one signal produced by an electrophysiological or electrochemical reaction occurring at the metal electrode, to form a transducer component. The posterior surface of the first substrate is stacked to the anterior surface of the second substrate. The first substrate is bonded to the second substrate to create an electrical interconnect between the first substrate and the second substrate. A sensing system is formed that is capable of interpreting the signal arising from the electrophysiological or electrochemical reaction to ascertain the level of some physiological or biochemical entity.
Yet another aspect of the present invention is a method for the heterogeneous and monolithic integration of a semiconductor-based solid microneedles sensor and a semiconductor-based CMOS circuitry transducer. The method includes bonding a plurality of pads located on the posterior surface of sensor to a plurality of pads on either the anterior or posterior surface of a transducer to facilitate electrical communication between a sensor and the transducer. The sensor comprises a plurality of solid microneedles on the anterior surface of a substrate, each of the plurality of microneedles comprising an addressable sensing electrode. The transducer comprises a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio; Each of the plurality of sensing electrodes is accessible on a posterior surface of the substrate by means of a plurality of vertically-oriented conducting channels, wherein at a location on the posterior surface in which each of plurality of vertically-oriented conducting channels exit from the substrate. A plurality of conductive pads are positioned to facilitate bonding to the surface of a second substrate.
Yet another aspect of the present invention is a method for the heterogeneous and monolithic integration of a semiconductor-based solid microneedles sensor and a semiconductor-based CMOS circuitry transducer. The method includes mating a first substrate to a second substrate such that a posterior surface of the first substrate is bonded to an anterior surface of the second substrate. The first substrate contains a transducer and the second substrate containing a sensor. The sensor comprises a plurality of solid microneedles on the anterior surface of a substrate. Each of the plurality of microneedles comprises an addressable sensing electrode. The transducer comprises a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. Each of the plurality of sensing electrodes is accessible on a posterior surface of the substrate by means of a plurality of vertically-oriented conducting channels, wherein at a location on the posterior surface in which each of plurality of vertically-oriented conducting channels exit from the substrate. A plurality of conductive pads are positioned to facilitate bonding to the surface of a second substrate.
Having briefly described the present invention, the above and further objects, features and advantages thereof will be recognized by those skilled in the pertinent art from the following detailed description of the invention when taken in conjunction with the accompanying drawings.
To facilitate increased patient compliance and improve the treatment of acute or chronic disease, body-adorned medical devices such as non-invasive sensor patches as well as minimally-invasive subcutaneously- and intracutaneously-implanted sensors have substantially expanded in use over the past decade. Much of this proliferation has been a result of advancements in electrochemical sensor technology, which enables the quantification of circulating analytes in physiological fluids (blood, interstitial fluid, etc.) in miniaturized and compact platforms. These platforms, which integrate the sensor and transducer constituents into a single device, have been applied to such embodiments as continuous glucose monitoring. Although the current state-of-the-art has resulted in the widespread utilization of body-worn devices in the healthcare domain, the realization of truly low-profile and potentially skin-conformal skin-adorned or skin-adhered medical devices remains elusive as current limitations with electronic device packaging often entails the mounting and interconnect, in a 2-dimensional fashion, of discrete components populating a printed circuit board.
The present invention is a method for the three-dimensional (“3D”) packaging and interconnection of heterogeneous, semiconductor-based systems for body-worn health and wellness devices, such as MEMS-fabricated microneedle arrays and CMOS-based transducers. One aspect of the present invention is a novel method of die attaching via stacking and interconnection of CMOS- and MEMS-based dies as a means to achieve 2.5D or 3D integration. Another aspect of the present invention is a method of fabricating CMOS and MEMS systems on geographically distinct regions of a shared surface of substrate whereby said systems are interconnected to one another by means of conductive traces or through-silicon vias. Another aspect of the present invention is a method of fabricating CMOS and MEMS on opposing surfaces of a substrate whereby interconnect between the two systems is facilitated by through-silicon vias. The ability to perform MEMS-to-CMOS packaging via stacked wire-bonding, reflow soldering of solder balls, or stud-bumping in conjunction with silicon or epoxy interposers enables the construction of vertically-integrated 2.5- or 3-dimensional self-contained sensing systems. Likewise, co-substrate integration of microneedles and CMOS circuitry represents another compelling solution enabled by through-silicon vias (TSVs), flip-chip bonding techniques, or a combination of these capabilities.
The monolithic integration of CMOS-based circuitry and microneedle-based transducers solves several noteworthy challenges confronting those developing technologies in the medical devices and wearable sensors domains. The present invention represents a novel approach to facilitating the synthesis of a heterogeneous, self-contained sensor-transducer system that addresses the shortcomings of the prior art while remaining amenable to highly scalable manufacturing processes.
These prior art shortcomings include the following:
(1) The necessity of interconnect of distinct microneedle-based sensors and CMOS-based transducers, as required for the readout of said microneedles, by means of integration as discrete packaged and mounted/bonded devices populating a printed circuit board: Limitation: A printed circuit board containing discrete microneedle and CMOS systems cannot be easily miniaturized beyond the xy-dimensions associated with said systems as well as the interconnects between the two, thereby placing a technological barrier to the realization of miniaturized skin-worn sensor devices. Moreover, routing electrical connections between two or more such discrete systems on a printed circuit board imposes added constraints of complexity and cost. Mitigation: The utilization of advanced semiconductor processing and packaging techniques facilitates the creation of 2.5- or 3-dimensional, self-contained microneedle-CMOS sensor-transducer systems or heterogeneously integrated microneedle-CMOS architectures sharing a common substrate.
(2) The interconnect of discrete microneedle-based sensors and CMOS-based transducers using conventional PCB traces: Limitation: Interconnect of distinct microneedle and CMOS systems on a printed circuit board is not amenable to maintaining signal fidelity, especially when such signals are analog in nature and reside in the nanoampere/microvolt (or lower) range. Mitigation: As the spatial extent of the interconnect between two electronic systems is directly proportional to noise ingress, the co-location of microneedle and CMOS systems on a shared substrate or the interconnect of said systems by means of solder balls/wire bonds serves to minimize the distance over which said systems interact and hence the noise imparted in the combined system. By reducing interconnect length between the microneedle sensor and CMOS transducer, the chief source of electronic noise and signal degradation is thus minimized.
(3) Inability to scale heterogeneous microneedle- and CMOS-based systems to dimensions enabling unobtrusive, conformal, and flexible skin-adorned medical patches: Limitation: Owing to their disparate manufacturing and packaging requirements, silicon micro-fabricated microneedles and CMOS circuitry have conventionally been packaged as mutually-exclusive, discrete entities populating a printed circuit board. Indeed, heterogeneous integration in a single package or on a single substrate presents difficulty owing to incompatibilities in manufacturing processes and packaging requirements. Mitigation: Employing a monolithic approach to microneedle and CMOS integration, either by means of co-locating the said constituents on the same substrate, or packaging the components as a single stacked entity, heralds the realization of highly miniaturized, self-contained sensing systems capable of direct integration into skin-adorned medical patches characterized by low footprint.
The technology disclosed herein specifies methods to achieve the heterogeneous and monolithic integration of semiconductor-based solid microneedles sensor and the semiconductor-based CMOS circuitry transducer required to interpret readings from the sensor. The sensor preferably contains one or a plurality of solid microneedles on an anterior surface of a substrate, each containing an addressable sensing electrode. The sensor is preferably designed to penetrate a biological interface to access a physiological fluid or tissue. The transducer preferably contains one or a plurality of integrated circuits using complementary metal oxide semiconductor (CMOS) technology. The transducer is preferably designed to control the sensor by applying a specific signal or stimulus to the sensor as well as interpreting the resulting electrical response of the sensor to the signal or stimulus. The transducer preferably includes at least one of the following components: a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. Three approaches may be leveraged to achieve this aim of heterogeneous integration of the sensor and the transducer.
The stacked substrate 10: The sensing electrodes are accessible on the opposing (posterior) surface of the substrate by means of vertically-oriented conducting channels known as through-substrate vias (TSVs), and as described in more detail in Windmiller, et al., U.S. patent application Ser. No. 15/913,709, filed on Mar. 6, 2018, for Methods For Achieving An Isolated Electrical Interface Between An Anterior Surface Of A Microneedle Structure And A Posterior Surface Of A Support Structure is hereby incorporated by reference in its entirety. At a location on a posterior surface in which the TSVs exit from the substrate, conductive pads are found to facilitate bonding to the surface of a second substrate. The conductive pads are preferably located on the posterior surface of the sensor, and are bonded to conductive pads on either the anterior or posterior surface of the transducer to facilitate an electrical communication between the sensor and the transducer. Bonding is achieved by at least one of: stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding. Optionally, the sensor and the transducer may be wire-bonded to achieve electrical interface between the two systems. Optionally, the transducer (following mating with the sensor) may be mated, in a similar fashion as above, to another CMOS-containing substrate. Optionally, the transducer (following mating with the sensor) may be wire-bonded or stud-bumped and soldered to a printed circuit board to enable electrical communication with discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.
The Co-Substrate Integration: The sensing electrodes are accessible on the opposing (posterior) surface of the substrate by means of vertically-oriented conducting channels known as through-substrate vias (TSVs). At a location on the posterior surface in which the TSVs exit from the substrate, conductive traces are found to route signals generated by the sensor to the transducer to facilitate an electrical communication between the sensor located on the anterior surface of substrate and the transducer located on the posterior surface of substrate. Optionally, the substrate (hereinafter referred to as the first substrate) may be mated to another CMOS-containing substrate (second substrate) such that the posterior surface of the first substrate (containing the transducer) is bonded to the anterior surface of the second substrate by means of at least one of: stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding. Optionally, the first substrate or the second substrate (if present) may be wire-bonded or stud-bumped and soldered to a printed circuit board to enable electrical communication with discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.
The Co-Planar Integration: The sensing electrodes are accessible on the same (anterior) surface of the substrate by means of horizontally-oriented conducting traces. The conductive traces route electrical signals generated by sensor to the transducer to facilitate an electrical communication between the sensor and the transducer, both co-located on spatially distinct regions on the anterior surface of the substrate. Optionally, the substrate (hereinafter referred to as the first substrate) may be mated to another CMOS-containing silicon die (second substrate) such that the posterior surface of the first substrate is bonded to the anterior surface of the second substrate by means of at least one of: stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding. Optionally, the first substrate or the second substrate may be wire-bonded or stud-bumped and soldered to a printed circuit board to enable electrical communication with discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.
Under each of the above scenarios, the substrate may comprise a semiconductor wafer or die selected from one of the Group IV elements (i.e. Silicon, Germanium), the Group VI elements (i.e. Selenium, Tellurium), composites comprising II-VI elements (i.e. Cadmium Sulfide, Zinc Oxide), and composites comprising III-V elements (i.e. Gallium Arsenide, Indium Phosphide); the TSV may comprise the doped or intrinsically conducting species of the above materials as well as a metal.
The microneedle sensor 5 breaches a biological interface to access a physiological fluid or tissue. The microneedle sensor 5 contains one or a plurality of solid microneedles on the anterior surface of a silicon substrate 10, each of the microneedle constituents contain an addressable sensing electrode in physical contact with the physiological fluid or tissue. In addition, the sensing electrode(s) are in direct electrical communication either with another region on the anterior surface of the silicon substrate (by means of metallic traces/conduits) or on the posterior surface of the substrate (by means of through-silicon vias 1). The microneedle sensor 5 is designed to stimulate, sustain, and provide a means to read out some electrophysiological or electrochemical signal or reaction at the electrode surface.
The CMOS transducer 30 converts some variations in electrophysiological or electrochemical quantities arising at the interface of the microneedle sensor 5 and the biological interface into an electrical signal or vice versa. The CMOS transducer 30 transduces the signal(s) produced by the microneedle sensor 5 to information capable of being interpreted to ascertain the level of some physiological or biochemical entity. The CMOS transducer 30 contains complementary metal oxide semiconductor circuitry, patterned on a silicon substrate, to implement at least one of the following functionalities: a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio. Optionally the CMOS transducer 30 can control the microneedle sensor 5 by applying a certain potential, current, or frequency-modulated signal while simultaneously quantifying the electrical response of the microneedle sensor 5. Optionally the CMOS transducer 30 can perform processing on the signal to mitigate noise and can feature a wireless capability to relay said raw or processed signal to another device. Optionally the CMOS transducer 30 can interface with a display to present the user with sensor readings.
The semiconductor substrates 10 provide a mechanical support for the implementation of sensor and transducer constituents. The semiconductor substrates 10 are comprised of a semiconductor wafer or die selected from one of the Group IV elements (i.e. Silicon, Germanium), the Group VI elements (i.e. Selenium, Tellurium), composites comprising II-VI elements (i.e. Cadmium Sulfide, Zinc Oxide), and composites comprising III-V elements (i.e. Gallium Arsenide, Indium Phosphide).
Through-substrate via 1 facilitate an electrical interconnect between anterior and posterior surfaces of a semiconductor substrate 10. The through-substrate vias 1 are comprised of a doped or intrinsically conducting species of the Group IV, Group VI semiconductor elements or binary semiconductor compounds comprising the II-VI and III-V elements. Optionally the through-substrate vias 1 may be comprised of a metal or metal alloy. In the case that the substrate 10 is comprised of silicon, this is also referred to as a through-silicon via 1.
Stud bumps/solder balls/epoxy 23 facilitate an electrical interconnect between two disparate substrates (silicon 10, PCB 35, or combination of the two).
Bond wire 50 facilitates an electrical interconnect between two disparate substrates (silicon 10, PCB 35, or combination of the two). The bond wire 50 is preferably comprised of a metal or metal alloy.
One embodiment is a skin-adorned physiological or biochemical sensing device 20. The device 20 comprises a first substrate 10 and a second substrate 15. The first substrate 10 comprises an anterior surface and a posterior surface. The first substrate 10 comprises an array of solid microneedles 5 on the anterior surface designed to penetrate a biological interface to access a physiological fluid or tissue. Each microneedle 5 contains an addressable metal electrode located on the surface of the microneedle 5 which is in electrical communication with a metal surface located on the posterior surface of the first substrate 10 by means of a conductive conduit 1, to form a microneedle sensor component 5 capable of electrical interface with the physiological fluid or tissue. The conductive conduit 1 preferably comprises at least one of a through-substrate via 1. The through-substrate via 1 is preferably comprised of a doped or intrinsically conducting semiconductor; said semiconductor includes at least one of silicon, germanium, silicon germanium, gallium arsenide, indium phosphide, gallium nitride, zinc oxide, and cadmium selenide. The second substrate 15 has an anterior and a posterior surface. The second substrate 15 comprises integrated circuitry 30 on the anterior surface designed to transduce at least one signal produced by an electrophysiological or electrochemical reaction occurring at the metal electrode, to form a transducer component. The posterior surface of the first substrate 10 is stacked to the anterior surface of the second substrate 15. The first substrate 10 is bonded to the second substrate 15 to create an electrical interconnect between the first substrate 10 and the second substrate 15. A sensing device 20 is formed that is capable of interpreting the signal arising from the electrophysiological or electrochemical reaction to ascertain the level of some physiological or biochemical entity.
The first substrate is preferably a semiconductor that includes at least one of silicon, germanium, silicon germanium, gallium arsenide, indium phosphide, gallium nitride, zinc oxide, and cadmium selenide.
The electrical interface preferably includes at least one of applying an electrical stimulus to said physiological fluid or tissue and detecting an electrical signal arising within said physiological fluid or tissue. The electrical stimulus includes at least one of a DC voltage, DC current, AC voltage, AC current, frequency-modulated signal, amplitude-modulated signal, or phase-modulated signal. The electrical signal includes at least one of a DC voltage, DC current, AC voltage, AC current, frequency-modulated signal, amplitude-modulated signal, or phase-modulated signal.
The integrated circuitry 30 preferably comprises at least one of a potentiostat, an analog front end, an amplifier, a filter, an analog-to-digital converter, microcontroller, and a wireless radio.
The bonding means is at least one of stud bumps, solder balls, direct bonding, surface activated bonding, plasma activated bonding, fusion bonding, metal layer bonding, anodic bonding, eutectic bonding, glass frit bonding, insulating layer bonding, adhesive bonding, thermocompression bonding, reactive bonding, transient liquid phase diffusion bonding, physical bonding, and chemical bonding.
The second substrate 15 is further attached to a PCB 35 by means of at least one of: wire bonds 50, stud bumps 23, and solder balls 23.
The PCB 35 preferably comprises discrete electrical or electronic devices such as, but not limited to, batteries, antennas, resistors, capacitors, inductors, diodes, transistors, and discrete semiconductor components.
McCanna et al., U.S. patent application Ser. No. 14/843,926, filed on Sep. 2, 2015, for a Miniaturized Sub-Nanoampere Sensitivity Low-Noise Potentiostat System is hereby incorporated by reference in its entirety.
Windmiller et al., U.S. patent application Ser. No. 14/955,850, filed on Dec. 1, 2015, for a Method And Apparatus For Determining Body Fluid Loss is hereby incorporated by reference in its entirety.
Windmiller, U.S. patent application Ser. No. 15/177,289, filed on Jun. 8, 2016, for a Methods And Apparatus For Interfacing A Microneedle-Based Electrochemical Biosensor With An External Wireless Readout Device is hereby incorporated by reference in its entirety.
Wang et al., U.S. Patent Publication Number 20140336487 for a Microneedle Arrays For Biosensing And Drug Delivery is hereby incorporated by reference in its entirety.
Windmiller, U.S. patent application Ser. No. 15/590,105 for a Tissue-Penetrating Electrochemical Sensor Featuring A Co Electrodeposited Thin Film Comprised Of A Polymer And Bio-Recognition Element is hereby incorporated by reference in its entirety.
Windmiller, et al., U.S. patent application Ser. No. 15/913,709, filed on Mar. 6, 2018, for Methods For Achieving An Isolated Electrical Interface Between An Anterior Surface Of A Microneedle Structure And A Posterior Surface Of A Support Structure is hereby incorporated by reference in its entirety.
PCT Application Number PCT/US17/55314 for an Electro Deposited Conducting Polymers For The Realization Of Solid-State Reference Electrodes For Use In Intracutaneous And Subcutaneous Analyte-selective Sensors is hereby incorporated by reference in its entirety.
From the foregoing it is believed that those skilled in the pertinent art will recognize the meritorious advancement of this invention and will readily understand that while the present invention has been described in association with a preferred embodiment thereof, and other embodiments illustrated in the accompanying drawings, numerous changes modification and substitutions of equivalents may be made therein without departing from the spirit and scope of this invention which is intended to be unlimited by the foregoing except as may appear in the following appended claim. Therefore, the embodiments of the invention in which an exclusive property or privilege is claimed are defined in the following appended claims.
The Present Application is a continuation application of U.S. patent application Ser. No. 15/961,793, filed on Apr. 24, 2018, which claims priority to U.S. Provisional Patent Application No. 62/492,142, filed on Apr. 29, 2017, each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4305401 | Reissmueller et al. | Dec 1981 | A |
4323996 | Ganter | Apr 1982 | A |
4407295 | Steuer et al. | Oct 1983 | A |
4450842 | Zick et al. | May 1984 | A |
4908117 | Kinlen et al. | Mar 1990 | A |
4969468 | Byers et al. | Nov 1990 | A |
5035711 | Aoki et al. | Jul 1991 | A |
5131390 | Sakaguchi et al. | Jul 1992 | A |
5279543 | Glikfeld et al. | Jan 1994 | A |
5286364 | Yacynych et al. | Feb 1994 | A |
5540828 | Yacynych | Jul 1996 | A |
5730714 | Guy et al. | Mar 1998 | A |
5766132 | Yasukawa et al. | Jun 1998 | A |
5832410 | Lin et al. | Nov 1998 | A |
5869078 | Baudino | Feb 1999 | A |
5953306 | Yi | Sep 1999 | A |
6036055 | Mogadam et al. | Mar 2000 | A |
6091975 | Daddona et al. | Jul 2000 | A |
6132449 | Lum et al. | Oct 2000 | A |
6132499 | Wong et al. | Oct 2000 | A |
6132755 | Eicher et al. | Oct 2000 | A |
6139718 | Kurnik et al. | Oct 2000 | A |
6269053 | Kawata et al. | Jul 2001 | B1 |
6284126 | Kurnik et al. | Sep 2001 | B1 |
6364890 | Lum et al. | Apr 2002 | B1 |
6413396 | Yang et al. | Jul 2002 | B1 |
6465091 | Ou-yang | Oct 2002 | B1 |
6471903 | Sherman et al. | Oct 2002 | B2 |
6527762 | Santini, Jr. et al. | Mar 2003 | B1 |
6551849 | Kenney | Apr 2003 | B1 |
6587705 | Kim et al. | Jul 2003 | B1 |
6599408 | Chan et al. | Jul 2003 | B1 |
6603987 | Whitson | Aug 2003 | B2 |
6611707 | Prausnitz et al. | Aug 2003 | B1 |
6793789 | Choi et al. | Sep 2004 | B2 |
6801041 | Karinka et al. | Oct 2004 | B2 |
6814845 | Wilson et al. | Nov 2004 | B2 |
6862466 | Ackerman | Mar 2005 | B2 |
6908453 | Fleming et al. | Jun 2005 | B2 |
7081195 | Simpson et al. | Jul 2006 | B2 |
7097776 | Govinda Raju | Aug 2006 | B2 |
7132054 | Kravitz et al. | Nov 2006 | B1 |
7262068 | Roy et al. | Aug 2007 | B2 |
7343188 | Sohrab | Mar 2008 | B2 |
7344499 | Prausnitz et al. | Mar 2008 | B1 |
7366556 | Brister et al. | Apr 2008 | B2 |
7415299 | Zimmermann et al. | Aug 2008 | B2 |
7429333 | Chiou et al. | Sep 2008 | B2 |
7456112 | Lee | Nov 2008 | B2 |
7471972 | Rhodes et al. | Dec 2008 | B2 |
7473244 | Frazier et al. | Jan 2009 | B2 |
7493232 | Surina | Feb 2009 | B1 |
7534330 | Yu et al. | May 2009 | B2 |
7583990 | Goode, Jr. | Sep 2009 | B2 |
7599726 | Goode, Jr. | Oct 2009 | B2 |
7613491 | Boock | Nov 2009 | B2 |
7645263 | Angel et al. | Jan 2010 | B2 |
7715893 | Kamath et al. | May 2010 | B2 |
7768408 | Reggiardo et al. | Aug 2010 | B2 |
7778680 | Goode, Jr. | Aug 2010 | B2 |
7797028 | Goode, Jr. | Sep 2010 | B2 |
7811231 | Jin et al. | Oct 2010 | B2 |
7837654 | Shumate et al. | Nov 2010 | B2 |
7885697 | Brister et al. | Feb 2011 | B2 |
7905833 | Brister et al. | Mar 2011 | B2 |
7917186 | Kamath et al. | Mar 2011 | B2 |
7949382 | Jina | May 2011 | B2 |
7959569 | Goode et al. | Jun 2011 | B2 |
8005526 | Martin et al. | Aug 2011 | B2 |
8010174 | Goode, Jr. | Aug 2011 | B2 |
8022292 | Arianpour et al. | Sep 2011 | B2 |
8064977 | Boock et al. | Nov 2011 | B2 |
8088321 | Ferguson et al. | Jan 2012 | B2 |
8094009 | Allen et al. | Jan 2012 | B2 |
8108023 | Mir et al. | Jan 2012 | B2 |
8110079 | Gooding et al. | Feb 2012 | B2 |
8125331 | Allen et al. | Feb 2012 | B2 |
8130095 | Allen et al. | Mar 2012 | B2 |
8160665 | Mischler et al. | Apr 2012 | B2 |
8160671 | Kamath et al. | Apr 2012 | B2 |
8160834 | Liang et al. | Apr 2012 | B2 |
8162901 | Gonnelli et al. | Apr 2012 | B2 |
RE43399 | Simpson et al. | May 2012 | E |
8216138 | McGarraugh | Jul 2012 | B1 |
8236368 | Jung et al. | Aug 2012 | B2 |
8249684 | Kamath et al. | Aug 2012 | B2 |
8257324 | Prausnitz et al. | Sep 2012 | B2 |
8280475 | Brister et al. | Oct 2012 | B2 |
8280476 | Jina | Oct 2012 | B2 |
8284046 | Allen et al. | Oct 2012 | B2 |
8287453 | Li et al. | Oct 2012 | B2 |
8308960 | Kälvesten et al. | Nov 2012 | B2 |
8346335 | Harper et al. | Jan 2013 | B2 |
8376945 | Hayter et al. | Feb 2013 | B2 |
8386004 | Kamath et al. | Feb 2013 | B2 |
8423114 | Simpson et al. | Apr 2013 | B2 |
8428678 | Kamath et al. | Apr 2013 | B2 |
8452369 | Huys | May 2013 | B2 |
8463350 | Kamath et al. | Jun 2013 | B2 |
8483793 | Simpson et al. | Jul 2013 | B2 |
8506529 | Yang | Aug 2013 | B1 |
8548553 | Kamath et al. | Oct 2013 | B2 |
8565848 | Brister et al. | Oct 2013 | B2 |
8574165 | Marsh | Nov 2013 | B2 |
8617069 | Bernstein et al. | Dec 2013 | B2 |
RE44695 | Simpson et al. | Jan 2014 | E |
8626257 | Li et al. | Jan 2014 | B2 |
8637351 | Kälvesten et al. | Jan 2014 | B2 |
8660628 | Wang et al. | Feb 2014 | B2 |
8708966 | Allen et al. | Apr 2014 | B2 |
8798799 | Deo et al. | Aug 2014 | B2 |
8815070 | Wang et al. | Aug 2014 | B2 |
8870763 | Yang et al. | Oct 2014 | B2 |
8882665 | Yang et al. | Nov 2014 | B2 |
9008743 | Hayter et al. | Apr 2015 | B2 |
9008745 | Pushpala et al. | Apr 2015 | B2 |
9055901 | Brister et al. | Jun 2015 | B2 |
9125625 | Wang et al. | Sep 2015 | B2 |
9182368 | Pushpala et al. | Nov 2015 | B2 |
9234872 | Homyk et al. | Jan 2016 | B2 |
9248273 | Guvanasen et al. | Feb 2016 | B2 |
9332934 | Hayter et al. | May 2016 | B2 |
9336423 | Goodnow et al. | May 2016 | B2 |
9357951 | Simpson et al. | Jun 2016 | B2 |
9386954 | Saini et al. | Jul 2016 | B2 |
9387000 | Corrie et al. | Jul 2016 | B2 |
9414778 | Mao et al. | Aug 2016 | B2 |
9420965 | Brauker et al. | Aug 2016 | B2 |
9532741 | Brauker et al. | Jan 2017 | B2 |
9551698 | Huys et al. | Jan 2017 | B2 |
9662056 | Budiman et al. | May 2017 | B2 |
9737247 | Wang et al. | Aug 2017 | B2 |
9743870 | Wang et al. | Aug 2017 | B2 |
9743871 | Simpson et al. | Aug 2017 | B2 |
9757061 | Shults et al. | Sep 2017 | B2 |
9770211 | Hayter et al. | Sep 2017 | B2 |
9804114 | Rhodes et al. | Oct 2017 | B2 |
9933387 | McCanna et al. | Apr 2018 | B1 |
9958409 | Gerber et al. | May 2018 | B2 |
10022076 | Hoss et al. | Jul 2018 | B2 |
10039480 | Brauker et al. | Aug 2018 | B2 |
10046114 | Biederman et al. | Aug 2018 | B1 |
10052055 | Li et al. | Aug 2018 | B2 |
10092207 | Windmiller | Oct 2018 | B1 |
10136846 | Wang et al. | Nov 2018 | B2 |
10173042 | Pushpala et al. | Jan 2019 | B2 |
10182748 | Catt et al. | Jan 2019 | B2 |
10188333 | Kamath et al. | Jan 2019 | B2 |
10228341 | Katsuki et al. | Mar 2019 | B2 |
10299712 | Brister et al. | May 2019 | B2 |
10327678 | Gottlieb et al. | Jun 2019 | B2 |
10492708 | Windmiller | Dec 2019 | B1 |
D875254 | Cooke et al. | Feb 2020 | S |
10549080 | Pushpala et al. | Feb 2020 | B2 |
10610103 | Brister et al. | Apr 2020 | B2 |
10709332 | Brister et al. | Jul 2020 | B2 |
10743800 | Larvenz et al. | Aug 2020 | B2 |
10820860 | Pushpala et al. | Nov 2020 | B2 |
10881334 | Facchinetti et al. | Jan 2021 | B2 |
10932700 | Simpson et al. | Mar 2021 | B2 |
10983083 | Harding et al. | Apr 2021 | B2 |
11020026 | Boock et al. | Jun 2021 | B2 |
11035872 | Boutelle et al. | Jun 2021 | B2 |
11045142 | Windmiller et al. | Jun 2021 | B1 |
11051724 | Pace et al. | Jul 2021 | B2 |
11123532 | Pushpala et al. | Sep 2021 | B2 |
11179068 | Pace et al. | Nov 2021 | B2 |
11197985 | Pushpala et al. | Dec 2021 | B2 |
11272866 | Pushpala et al. | Mar 2022 | B2 |
11272885 | Pushpala et al. | Mar 2022 | B2 |
11291390 | Pushpala et al. | Apr 2022 | B2 |
11331022 | Halac et al. | May 2022 | B2 |
11359300 | Beer et al. | Jun 2022 | B1 |
11406818 | Windmiller | Aug 2022 | B2 |
11478194 | Windmiller et al. | Oct 2022 | B2 |
11596332 | Shults et al. | Mar 2023 | B2 |
11654270 | Mansfield, III et al. | May 2023 | B2 |
D988160 | Morelock | Jun 2023 | S |
11672965 | Mansfield, III et al. | Jun 2023 | B2 |
20020004640 | Conn et al. | Jan 2002 | A1 |
20020020688 | Sherman et al. | Feb 2002 | A1 |
20020055704 | Scott et al. | May 2002 | A1 |
20020072784 | Norman, Jr. et al. | Jun 2002 | A1 |
20020105080 | Speakman | Aug 2002 | A1 |
20020187556 | Shartle et al. | Dec 2002 | A1 |
20030088166 | Say et al. | May 2003 | A1 |
20030095582 | Ackley | May 2003 | A1 |
20030100040 | Bonnecaze et al. | May 2003 | A1 |
20030104119 | Wilson et al. | Jun 2003 | A1 |
20030135158 | Gonnelli | Jul 2003 | A1 |
20030208167 | Prausnitz et al. | Nov 2003 | A1 |
20030225360 | Eppstein et al. | Dec 2003 | A1 |
20030235817 | Bartkowiak et al. | Dec 2003 | A1 |
20040065158 | Schrepfer et al. | Apr 2004 | A1 |
20040082875 | Donoghue et al. | Apr 2004 | A1 |
20040220625 | Silvestri et al. | Nov 2004 | A1 |
20050036020 | Li et al. | Feb 2005 | A1 |
20050137536 | Gonnelli | Jun 2005 | A1 |
20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
20050267440 | Herman et al. | Dec 2005 | A1 |
20050272989 | Shah et al. | Dec 2005 | A1 |
20060015061 | Kuo et al. | Jan 2006 | A1 |
20060016700 | Brister et al. | Jan 2006 | A1 |
20060173259 | Flaherty et al. | Aug 2006 | A1 |
20060264716 | Zander | Nov 2006 | A1 |
20060281121 | Unger et al. | Dec 2006 | A1 |
20070078445 | Malloy | Apr 2007 | A1 |
20070169533 | Shah et al. | Jul 2007 | A1 |
20070170054 | Wilsey | Jul 2007 | A2 |
20070213044 | Steingart et al. | Sep 2007 | A1 |
20070282246 | Henley | Dec 2007 | A1 |
20080009800 | Nickel | Jan 2008 | A1 |
20080009801 | Nickel | Jan 2008 | A1 |
20080027369 | Carter et al. | Jan 2008 | A1 |
20080033269 | Zhang | Feb 2008 | A1 |
20080097280 | Martin et al. | Apr 2008 | A1 |
20080097352 | Beck et al. | Apr 2008 | A1 |
20080119707 | Stafford | May 2008 | A1 |
20080154107 | Jina | Jun 2008 | A1 |
20080156661 | Cooper et al. | Jul 2008 | A1 |
20080213461 | Gill et al. | Sep 2008 | A1 |
20080221408 | Hoarau et al. | Sep 2008 | A1 |
20080234562 | Jina | Sep 2008 | A1 |
20080255434 | Hayter et al. | Oct 2008 | A1 |
20080275327 | Faarbaek et al. | Nov 2008 | A1 |
20090057148 | Wieder et al. | Mar 2009 | A1 |
20090066348 | Shin et al. | Mar 2009 | A1 |
20090069651 | Zimmermann et al. | Mar 2009 | A1 |
20090069697 | Frazier et al. | Mar 2009 | A1 |
20090084678 | Joshi et al. | Apr 2009 | A1 |
20090088652 | Tremblay | Apr 2009 | A1 |
20090090623 | Chuang et al. | Apr 2009 | A1 |
20090099427 | Jina et al. | Apr 2009 | A1 |
20090101498 | Papadimitrakopoulos et al. | Apr 2009 | A1 |
20090131778 | Jina et al. | May 2009 | A1 |
20090143761 | Cantor et al. | Jun 2009 | A1 |
20090152598 | Baek et al. | Jun 2009 | A1 |
20090191616 | Lu et al. | Jul 2009 | A1 |
20090198118 | Hayter et al. | Aug 2009 | A1 |
20090218239 | Gooding et al. | Sep 2009 | A1 |
20090259118 | Feldman et al. | Oct 2009 | A1 |
20090294306 | Feldman et al. | Dec 2009 | A1 |
20100006451 | Gordon et al. | Jan 2010 | A1 |
20100021637 | Revol et al. | Jan 2010 | A1 |
20100025238 | Gottlieb et al. | Feb 2010 | A1 |
20100030045 | Gottlieb et al. | Feb 2010 | A1 |
20100049021 | Jina et al. | Feb 2010 | A1 |
20100052892 | Allen et al. | Mar 2010 | A1 |
20100052897 | Allen et al. | Mar 2010 | A1 |
20100052898 | Allen et al. | Mar 2010 | A1 |
20100052915 | Allen et al. | Mar 2010 | A1 |
20100056873 | Allen et al. | Mar 2010 | A1 |
20100137779 | Seitz | Jun 2010 | A1 |
20100200538 | Petisce et al. | Aug 2010 | A1 |
20100279377 | Shah et al. | Nov 2010 | A1 |
20100286803 | Tillotson et al. | Nov 2010 | A1 |
20110027127 | Simpson et al. | Feb 2011 | A1 |
20110077490 | Simpson et al. | Mar 2011 | A1 |
20110105871 | Zimmermann et al. | May 2011 | A1 |
20110140703 | Chiao et al. | Jun 2011 | A1 |
20110224515 | Mir et al. | Sep 2011 | A1 |
20110230736 | Tepper et al. | Sep 2011 | A1 |
20110237925 | Yue et al. | Sep 2011 | A1 |
20110247934 | Wang et al. | Oct 2011 | A1 |
20110275918 | Yamashita et al. | Nov 2011 | A1 |
20110306853 | Black et al. | Dec 2011 | A1 |
20110319787 | Lamoise et al. | Dec 2011 | A1 |
20120018302 | Shiraki et al. | Jan 2012 | A1 |
20120037515 | Solanki | Feb 2012 | A1 |
20120067734 | Wang et al. | Mar 2012 | A1 |
20120078071 | Bohm et al. | Mar 2012 | A1 |
20120123232 | Najarian et al. | May 2012 | A1 |
20120172692 | Tamada et al. | Jul 2012 | A1 |
20120209244 | Gray | Aug 2012 | A1 |
20120277629 | Bernstein et al. | Nov 2012 | A1 |
20120323097 | Chowdhury | Dec 2012 | A9 |
20130053660 | Shieh | Feb 2013 | A1 |
20130065257 | Wang et al. | Mar 2013 | A1 |
20130135158 | Faraone et al. | May 2013 | A1 |
20130144131 | Wang et al. | Jun 2013 | A1 |
20130158376 | Hayter et al. | Jun 2013 | A1 |
20130225956 | Huang et al. | Aug 2013 | A1 |
20130281808 | Shieh | Oct 2013 | A1 |
20130338746 | Guvanasen et al. | Dec 2013 | A1 |
20130345597 | Hagino et al. | Dec 2013 | A1 |
20140135679 | Mann et al. | May 2014 | A1 |
20140259652 | Pushpala et al. | Sep 2014 | A1 |
20140275897 | Pushpala et al. | Sep 2014 | A1 |
20140275899 | Gottlieb et al. | Sep 2014 | A1 |
20140275907 | Feldman et al. | Sep 2014 | A1 |
20140303471 | Rajaraman | Oct 2014 | A1 |
20140336487 | Wang et al. | Nov 2014 | A1 |
20140378804 | Kalvesten et al. | Dec 2014 | A1 |
20150073238 | Matsumoto et al. | Mar 2015 | A1 |
20150126834 | Wang et al. | May 2015 | A1 |
20150208970 | Huang | Jul 2015 | A1 |
20150243851 | Lee et al. | Aug 2015 | A1 |
20150276758 | Addisu | Oct 2015 | A1 |
20150313527 | Renlund | Nov 2015 | A1 |
20160029937 | Sia et al. | Feb 2016 | A1 |
20160058342 | Maiz-Aguinaga | Mar 2016 | A1 |
20160095541 | Wang et al. | Apr 2016 | A1 |
20160095547 | Wang et al. | Apr 2016 | A1 |
20160139069 | Wang | May 2016 | A1 |
20160157764 | Di Palma | Jun 2016 | A1 |
20160158514 | Stoeber et al. | Jun 2016 | A1 |
20160166184 | Teng et al. | Jun 2016 | A1 |
20160258945 | Malima et al. | Sep 2016 | A1 |
20160270704 | Deturk | Sep 2016 | A1 |
20160296149 | Polsky et al. | Oct 2016 | A1 |
20160302687 | Lee et al. | Oct 2016 | A1 |
20160370377 | Ahmad | Dec 2016 | A1 |
20170003766 | Budiman | Jan 2017 | A1 |
20170007813 | Negi et al. | Jan 2017 | A1 |
20170035331 | Parajape et al. | Feb 2017 | A1 |
20170127989 | Feldman et al. | May 2017 | A1 |
20170128009 | Pushpala et al. | May 2017 | A1 |
20170164881 | Fujita et al. | Jun 2017 | A1 |
20170251959 | Feldman et al. | Sep 2017 | A1 |
20170251960 | Crouther et al. | Sep 2017 | A1 |
20170347925 | Wang et al. | Dec 2017 | A1 |
20180116572 | Simpson et al. | May 2018 | A1 |
20180140235 | Pushpala et al. | May 2018 | A1 |
20180279929 | Huang | Oct 2018 | A1 |
20180317820 | Pace et al. | Nov 2018 | A1 |
20180338712 | Cass | Nov 2018 | A1 |
20190008425 | Srinivasan et al. | Jan 2019 | A1 |
20190022365 | Chowdhury et al. | Jan 2019 | A1 |
20190029577 | Koelker et al. | Jan 2019 | A1 |
20190090811 | Reitz et al. | Mar 2019 | A1 |
20190091455 | Reitz et al. | Mar 2019 | A1 |
20190094169 | Shah et al. | Mar 2019 | A1 |
20190110724 | Kamath et al. | Apr 2019 | A1 |
20190125223 | Wang et al. | May 2019 | A1 |
20190167167 | Mitchell et al. | Jun 2019 | A1 |
20190209095 | Kamath et al. | Jul 2019 | A1 |
20190223795 | Patolsky et al. | Jul 2019 | A1 |
20190224712 | Petisce et al. | Jul 2019 | A1 |
20190241926 | Mckinlay et al. | Aug 2019 | A1 |
20190261907 | Brister et al. | Aug 2019 | A1 |
20190274599 | Polsky et al. | Sep 2019 | A1 |
20190274600 | Pesantez et al. | Sep 2019 | A1 |
20190298210 | Bennet et al. | Oct 2019 | A1 |
20190307379 | Boock et al. | Oct 2019 | A1 |
20190309433 | Sattayasamitsathit et al. | Oct 2019 | A1 |
20190310219 | Boock | Oct 2019 | A1 |
20190357827 | Li et al. | Nov 2019 | A1 |
20200029876 | Brister et al. | Jan 2020 | A1 |
20200037938 | Rong et al. | Feb 2020 | A1 |
20200101286 | Windmiller et al. | Apr 2020 | A1 |
20200121902 | Pushpala et al. | Apr 2020 | A1 |
20200178853 | Pushpala et al. | Jun 2020 | A1 |
20200187778 | Brister et al. | Jun 2020 | A1 |
20200214566 | Allen et al. | Jul 2020 | A1 |
20200254240 | Windmiller et al. | Aug 2020 | A1 |
20200297997 | Windmiller et al. | Sep 2020 | A1 |
20200305771 | Feldman et al. | Oct 2020 | A1 |
20200359949 | Brauker et al. | Nov 2020 | A1 |
20200405234 | Pushpala et al. | Dec 2020 | A1 |
20210045663 | Simpson et al. | Feb 2021 | A1 |
20210045665 | Simpson et al. | Feb 2021 | A1 |
20210045666 | Simpson et al. | Feb 2021 | A1 |
20210100452 | Brister et al. | Apr 2021 | A1 |
20210100504 | Pushpala et al. | Apr 2021 | A1 |
20210100505 | Pushpala et al. | Apr 2021 | A1 |
20210183508 | Parker et al. | Jun 2021 | A1 |
20210187286 | Windmiller et al. | Jun 2021 | A1 |
20210190719 | LaTour et al. | Jun 2021 | A1 |
20210345916 | Boock et al. | Nov 2021 | A1 |
20210353229 | Pierart et al. | Nov 2021 | A1 |
20210379370 | Windmiller et al. | Dec 2021 | A1 |
20210386338 | Zhang et al. | Dec 2021 | A1 |
20210393201 | Morelock et al. | Dec 2021 | A1 |
20220031244 | Windmiller et al. | Feb 2022 | A1 |
20220047190 | Taylor et al. | Feb 2022 | A1 |
20220054813 | Pushpala et al. | Feb 2022 | A1 |
20220054814 | Pushpala et al. | Feb 2022 | A1 |
20220104773 | Lee et al. | Apr 2022 | A1 |
20220151516 | Wang et al. | May 2022 | A1 |
20220151518 | Pushpala et al. | May 2022 | A1 |
20220151519 | Pushpala et al. | May 2022 | A1 |
20220151558 | Pushpala et al. | May 2022 | A1 |
20220175278 | Campbell et al. | Jun 2022 | A1 |
20220175279 | Pushpala et al. | Jun 2022 | A1 |
20220175282 | Hoss et al. | Jun 2022 | A1 |
20220214300 | Wang et al. | Jul 2022 | A1 |
20220225901 | Chapman et al. | Jul 2022 | A1 |
20220233107 | Pushpala et al. | Jul 2022 | A1 |
20220249189 | Choi et al. | Aug 2022 | A1 |
20220298291 | Shin et al. | Sep 2022 | A1 |
20220322975 | Baker et al. | Oct 2022 | A1 |
20220322977 | Simpson et al. | Oct 2022 | A1 |
20220370011 | Windmiller et al. | Nov 2022 | A1 |
20230074798 | Tangney et al. | Mar 2023 | A1 |
20230094419 | Mansfield, III et al. | Mar 2023 | A1 |
20230099617 | Mansfield, III et al. | Mar 2023 | A1 |
20230137258 | Windmiller | May 2023 | A1 |
20230190147 | Campbell et al. | Jun 2023 | A1 |
Number | Date | Country |
---|---|---|
101068591 | Nov 2007 | CN |
112617822 | Apr 2021 | CN |
1006868 | Jun 2004 | EP |
1 372 602 | Apr 2007 | EP |
1792565 | Oct 2008 | EP |
1 187 653 | Mar 2010 | EP |
2 898 821 | Dec 2017 | EP |
3 381 370 | Oct 2018 | EP |
H-02-031741 | Feb 1990 | JP |
H-07-275227 | Oct 1995 | JP |
2003-038464 | Feb 2003 | JP |
2003-038465 | Feb 2003 | JP |
2005-087613 | Apr 2005 | JP |
2006-510467 | Apr 2005 | JP |
2005-525141 | Aug 2005 | JP |
2005-322591 | Nov 2005 | JP |
2008-512162 | Apr 2008 | JP |
2008-540013 | Nov 2008 | JP |
10-2016-0108111 | Sep 2016 | KR |
WO-0074763 | Dec 2000 | WO |
WO-0074763 | Dec 2000 | WO |
WO-2006060106 | Jun 2006 | WO |
WO-2006093422 | Sep 2006 | WO |
WO-2006116242 | Nov 2006 | WO |
WO-2006116242 | Nov 2006 | WO |
WO-2007040938 | Apr 2007 | WO |
WO-2009034313 | Mar 2009 | WO |
WO-2009034313 | Mar 2009 | WO |
WO-2009064164 | May 2009 | WO |
WO-2009064164 | May 2009 | WO |
WO-2009124095 | Oct 2009 | WO |
WO-2010014959 | Feb 2010 | WO |
WO-2010014959 | Feb 2010 | WO |
WO-2010022252 | Feb 2010 | WO |
WO-2010022252 | Feb 2010 | WO |
WO-2010045247 | Apr 2010 | WO |
WO-2010059276 | May 2010 | WO |
WO-2010120364 | Oct 2010 | WO |
WO-2010120364 | Oct 2010 | WO |
WO-2011056095 | May 2011 | WO |
WO-2012020332 | Feb 2012 | WO |
WO-2012020332 | Feb 2012 | WO |
WO-2012142625 | Oct 2012 | WO |
WO-2012142625 | Oct 2012 | WO |
WO-2013058879 | Apr 2013 | WO |
WO-2013058879 | Apr 2013 | WO |
WO-2014120114 | Aug 2014 | WO |
WO-2015073459 | May 2015 | WO |
WO-2016189301 | Dec 2016 | WO |
WO-2017129980 | Aug 2017 | WO |
WO-2017189707 | Nov 2017 | WO |
WO-2018017196 | Jan 2018 | WO |
WO-2018071265 | Apr 2018 | WO |
WO-2018164886 | Sep 2018 | WO |
WO-2018170363 | Sep 2018 | WO |
WO-2019156934 | Aug 2019 | WO |
WO-2019222615 | Nov 2019 | WO |
WO-2019239258 | Dec 2019 | WO |
WO-2020023804 | Jan 2020 | WO |
WO-2021015389 | Jan 2021 | WO |
WO-2021025260 | Feb 2021 | WO |
WO-2021086690 | May 2021 | WO |
WO-2021118124 | Jun 2021 | WO |
WO-2021118431 | Jun 2021 | WO |
WO-2022026764 | Feb 2022 | WO |
WO-2022066985 | Mar 2022 | WO |
WO-2022066992 | Mar 2022 | WO |
WO-2022090741 | May 2022 | WO |
WO-2022136785 | Jun 2022 | WO |
WO-2023055755 | Apr 2023 | WO |
WO-2023064877 | Apr 2023 | WO |
WO-2023133468 | Jul 2023 | WO |
Entry |
---|
Abbot press release (2020). “New late-breaking data show use of abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not,” 3 pages. |
American Diabetes Association® Press Release (2020). “American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans,” 4 pages. |
Bantle, J.P. et al. (1997). “Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid,” J. Lab. Clin. Med. 130:436-441. |
Beckles, G.L. et al. (2016). “Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014,” MMWR 65:1265-1269. |
Cao, J. et al. (2017). “Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system,” Pract. Lab. Med. 9:24-27. |
Castle, J.R. et al. (2012). “The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes,” Diabetes Care 35:706-710. |
Chang, H. et al. (2017). “A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis,” Adv. Mater. 29:1702243. |
Dexcom (2020). Analyst Day Presentation, 27 total pages. |
Dexcom (2020). Analyst Day Presentation, 19 total pages. |
Diabetes Care (2021). “7. Diabetes Technology: Standards of Medical Care in Diabetes—2021,” Diabetes Care 44(Supplement 1):S85-S99. |
Donnelly, R.F. et al. (2007). “Microstructured Devices for Transdermal Drug Delivery and Minimally-Invasive Patient Monitoring,” Recent Patents on Drug Delivery & Formulation 1:195-200. |
Extended European Search Report dated May 8, 2015, for EP Application No. 12 842 020.5, filed on Aug. 31, 2012, 7 pages. |
Extended European Search Report dated Oct. 27, 2022, for EP Application No. 21 850 331.6, filed on Jul. 29, 2021, 8 pages. |
Fang, M. et al. (2021). “Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018,” N. Engl. Med. 384:2219-2228. |
Final Office Action dated Aug. 19, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages. |
Final Office Action dated Nov. 28, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 34 pages. |
Final Office Action dated May 18, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 23 pages. |
Final Office Action dated Dec. 7, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages. |
Final Office Action dated May 21, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 11 pages. |
Final Office Action dated Jun. 9, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 24 pages. |
Final Office Action dated Sep. 23, 2021, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 17 pages. |
Final Office Action dated May 9, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 17 pages. |
Final Office Action dated Aug. 15, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
Final Office Action dated Oct. 27, 2022, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 21 pages. |
French, D.P. et al. (2008). “Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial,” Diav. Med. 25:1218-1228. |
Gittard, S.D. et al. (2009). “Fabrication of Polymer Microneedles Using a Two-Photon Polymerization and Micromolding Process,” J. Diabetes Sci. Technol. 3:304-311. |
Grady, M. et al. (2017). “Examining the Impact of a Novel Blood Glucose Monitor With Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level,” JMIR Diabetes 2:e24. |
Grady, M. et al. (2018). “Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study),” J. Diab. Sci. Tech. 12:1211-1219. |
Groenendaal, W. et al. (2008). “Modeling Glucose and Water Dynamics in Human Skin,” Diab. Tech. Therap. 10:283-293. |
International Search Report dated Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 7 pages. |
International Search Report dated Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 2 pages. |
International Search Report dated Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 2 pages. |
International Search Report dated Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages. |
International Search Report dated Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 2 pages. |
International Search Report dated Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 4 pages. |
Jeon, G. et al. (2011). “Electrically Actuatable Smart Nanoporous Membrane for Pulsatile Drug Release,” Nano Lett. 11:1284-1288. |
Jina, A et al. (2014). “Design, development, and evaluation of a novel microneedle array-based continuous glucose monitor,” J. Diabetes Sci. Technol. 8:483-487. |
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). “Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes,” N. Engl. Med. 359:1464-1476. |
Karter, A.J. et al. (2021). “Association of Real-time Continuous Glucose Monitoring with Glycemic Control and Acute Metabolic Events Among Patients with Insulin-Treated Diabetes,” JAMA 325:2273-2284. |
Lhernould, M.S. et al. (2015). “Review of Patents for Microneedle Application Devices Allowing Fluid Injections Through the Skin,” Recent Patents on Drug Delivery & Formulation 9:146-157. |
Malitesta et al. (1990). “Glucose fast-response amperometric sensor based on glucose oxidase immobilized in an electropolymerized poly(o-phenylenediamine) film,” Anal. Chem. 62:2735-2740. |
Martens, T. et al. (2021). “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin a Randomized Clinical Trial,” JAMA 325:2262-2272. |
Mcclatchey, P.M. et al. (2019). “Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays,” Diabetes 68:1892-1901. |
Miller, P.R. et al. (2011). “Integrated carbon fiber electrodes within hollow polymer microneedles for transdermal electrochemical sensing,” BioMicrofluidics 5(1):013415. |
Mohan, A.M. (2017). “Continuous minimally-invasive alcohol monitoring using microneedle sensor arrays,” Biosensors and Bioelectronics 91:574-579. |
Neerken, S. et al. (2004). “Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography,” J. Biomed. Optics 9:274-281. |
Non-Final Office Action dated Mar. 10, 2016, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 15 pages. |
Non-Final Office Action dated Mar. 30, 2016, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 31 pages. |
Non-Final Office Action dated Mar. 9, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 17 pages. |
Non-Final Office Action dated Apr. 6, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 32 pages. |
Non-Final Office Action dated Nov. 1, 2017, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 19 pages. |
Non-Final Office Action dated Jan. 19, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 11 pages. |
Non-Final Office Action dated Apr. 13, 2020, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 13 pages. |
Non-Final Office Action dated Sep. 3, 2020, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 19 pages. |
Non-Final Office Action dated Sep. 16, 2020, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 15 pages. |
Non-Final Office Action dated Oct. 16, 2020, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 13 pages. |
Non-Final Office Action dated Nov. 4, 2021, for U.S. Appl. No. 16/169,939, filed Oct. 24, 2018, 20 pages. |
Non-Final Office Action dated Nov. 26, 2021, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 15 pages. |
Non-Final Office Action dated Nov. 29, 2021, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 14 pages. |
Non-Final Office Action dated Apr. 8, 2022, for U.S. Appl. No. 17/650,056, filed Feb. 4, 2022, 14 pages. |
Non-Final Office Action dated May 13, 2022, for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 20 pages. |
Non-Final Office Action dated Dec. 21, 2022, for U.S. Appl. No. 16/051,398, filed Jul. 31, 2018, 12 pages. |
Non-Final Office Action dated Jan. 27, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 15 pages. |
Non-Final Office Action dated Feb. 16, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 8 pages. |
Notice of Allowance dated Jul. 6, 2017, for U.S. Appl. No. 14/965,755, filed Dec. 10, 2015, 12 pages. |
Notice of Allowance dated Jul. 12, 2017, for U.S. Appl. No. 14/342,536, filed Jul. 30, 2014, 14 pages. |
Notice of Allowance dated Feb. 13, 2018, for U.S. Appl. No. 14/843,926, filed Sep. 2, 2015, 8 pages. |
Notice of Allowance dated Aug. 24, 2018, for U.S. Appl. No. 15/687,145, filed Aug. 25, 2017, 7 pages. |
Notice of Allowance dated May 25, 2021, for U.S. Appl. No. 15/961,793, filed Apr. 24, 2018, 11 pages. |
Notice of Allowance dated Sep. 12, 2022, for U.S. Appl. No. 17/389,153, filed Jul. 29, 2021, 8 pages. |
Polonsky, W.H. et al. (2011). “A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?” Curr. Med. Res. & Opinion 27:31-37. |
Rigla, M. et al. (2018). “Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy,” Diabetes Technology & Therapeutics 20:296-302. |
Sachdeva, V. et al. (2011). “Microneedles and their applications,” Recent Patents on Drug Delivery & Formulation 5:95-132. |
Sheikh, Z. et al. (2015). “Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials,” Materials 8:5671-5701. |
Shi, T. et al. (2016). “Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes,” J. Diab. Res. vol. 2016, 9 pages. |
Singh, T.R.R. et al. (2010). “Microporation techniques for enhanced delivery of therapeutic agents,” Recent Patents on Drug Delivery & Formulation 4:1-17. |
Swedish Search Report dated Feb. 3, 2023 for SE Application No. 2350067-1, 7 pages. |
Texas Instruments (Sep. 2007). Data sheet for a LMP2234 quad micropower, 1.6V, precision, operational amplifier with CMOS input, Sep. 2007, revised Mar. 2013, 31 total pages. |
Windmiller, J.R. (2012). “Molecular scale biocomputing: An enzyme logic approach,” University of California, San Diego, A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Electrical Engineering (Photonics), 78 total pages. |
Windmiller, J.R. et al. (2011). “Bicomponent microneedle array biosensor for minimally-invasive glutamate monitoring,” Electroanalysis 23:2302-2309. |
Windmiller, J.R. et al. (2011). “Microneedle array-based carbon paste amperometric sensors and biosensors,” Analyst 136:1846-1851. |
Written Opinion of the International Searching Authority dated Dec. 30, 2021, for PCT Application No. PCT/US2021/043786, filed on Jul. 29, 2021, 10 pages. |
Written Opinion of the International Searching Authority dated Sep. 10, 2020, for PCT Application No. PCT/US2020/037379, filed on Jun. 12, 2020, 4 pages. |
Written Opinion of the International Searching Authority dated Feb. 4, 2021, for PCT Application No. PCT/US2020/056517, filed on Oct. 20, 2020, 5 pages. |
Written Opinion of the International Searching Authority dated Sep. 30, 2021, for PCT Application No. PCT/US2021/040385, filed on Jul. 2, 2021, 2 pages. |
Written Opinion of the International Searching Authority dated Aug. 29, 2022, for PCT Application No. PCT/US2022/028196, filed on May 6, 2022, 5 pages. |
Written Opinion of the International Searching Authority dated Jun. 27, 2013, for PCT Application No. PCT/US2012/053544, filed on Aug. 31, 2012, 15 pages. |
Yoon, Y. et al. (2013). “Fabrication of a Microneedle/CNT Hierarchical Micro/Nano Surface Electrochemical Sensor and Its In-Vitro Glucose Sensing Characterization,” Sensors 13:16672-16681. |
Al Hayek et al., “Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study” Cureus Oct. 27, 2020; 12(10):e11195. doi: 10.7759/cureus.11195. |
Allen et al., “Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial” Diabetes Res Clin Pract. Jun. 2008; 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006. |
Barrett et al., “Risk for Newly Diagnosed Diabetes 30 Days After SARS-COV-2 Infection Among Persons Aged 18 Years—United States, Mar. 1, 2020-Jun. 28, 2021” MMWR Morb Mortal Wkly Rep. Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2. |
Brown, C., “Design of Electronics for Wearable Electrochemical Sensors”, University of California, San Diego, 2019, 39 pgs. |
Centers for Disease Control, “National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States” (2020) 32 pages. |
Dunkin et al., “Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers” Plast Reconstr Surg. May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0. |
Ehrhardt et al, “Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring” Journal of Diabetes Science and Technology Mar. 2019; 13(2):271-275. |
Ehrhardt et al., “Continuous Glucose Monitoring As a Behavior Modification Tool” Clin Diabetes. Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037. |
Ehrhardt et al, “The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus” Journal of Diabetes Science and Technology May 2011; 5(3):668-675. |
Extended European Search Report dated Mar. 30, 2023, for European Application No. EP20881425.1, 8 pages. |
Fonda et al., “The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes” Journal of Diabetes Science and Technology (2016) 10(4):898-904. |
Han et al., “The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?” Journal of Diabetes Science and Technology (2020) 14(3):595-600. |
Han et al., “The YSI 2300 Analyzer Replacement Meeting Report” Journal of Diabetes Science and Technology (2020) 14(3):679-686. |
Non-Final Office Action dated Mar. 9, 2023 for U.S. Appl. No. 17/389,156, filed Jul. 29, 2021, 24 pages. |
Non-Final Office Action dated May 2, 2023 for U.S. Appl. No. 15/913,709, filed Mar. 6, 2018, 18 pages. |
Non-Final Office Action dated May 24, 2023 for U.S. Appl. No. 18/086,543, filed Dec. 21, 2022, 19 pages. |
Non-Final Office Action dated Jun. 2, 2023, for U.S. Appl. No. 17/367,274, filed Jul. 2, 2021, 27 pages. |
Non-Final Office Action dated Jun. 20, 2023, for U.S. Appl. No. 17/073,331, filed Oct. 17, 2020, 10 pages. |
Notice of Allowance dated Jun. 12, 2023, for U.S. Appl. No. 17/971,415, filed Oct. 21, 2022, 14 pages. |
Notice of Allowance dated Jun. 12, 2023, for U.S. Appl. No. 17/738,990, filed May 6, 2022, 7 pages. |
Sharifi et al., “Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring” Journal of Diabetes Science and Technology (2016) 10(3):669-678. |
Turner et al., “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)” The Lancet Sep. 1998; 352(9131):837-853. |
Vigersky et al., “Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes” Diabetes Care Jan. 2012; 35:32-38. |
Wolicki et al., “Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration” Centers for Disease Control and Prevention (2021) 17 pages. |
World Health Organization, “Diabetes”, Sep. 16, 2022, 5 pages. |
Young et al., “Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial” JAMA Intern Med. Jul. 2017; 177(7):920-929. |
Number | Date | Country | |
---|---|---|---|
62492142 | Apr 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15961793 | Apr 2018 | US |
Child | 17349234 | US |